Elevance Health Inc (ELV)

Rating: SELL

SELL (5-tier) · high-risk optionality · conviction: medium

EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.

General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.

Investment Committee Summary

📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.

Rating Bridge

Rating = SELL because:

• Probability-weighted scenario value implies -10% vs spot
• Monte Carlo median implies -21% vs spot
• DCF fair value implies -25% vs spot — but this is terminal-value sensitive (exit-multiple $314 vs Gordon $437, 39% apart), so it carries less weight
• Bear case (Structural — Medicare/Medicaid Reform / MLR Squeeze) downside is -62% vs spot
• Net: reward/risk of 0.2× warrants a Sell.

Investment Thesis

At 386.73 the market prices ELV near 14x forward earnings, a discount to the payer peer median around 20x and below UNH at roughly 22x. Spot implies the market expects membership growth to persist but treats the margin as structurally capped in the low-3s, with Medicaid and reform risk overhanging. The engine's probability-weighted target of 377.86 sits fractionally below spot, so the rating is HOLD. The disagreement is narrow: the base path assumes an 8% top line on a 3.6% operating margin at 14x, producing roughly 28.5 of EPS, close to where the tape already trades. Upside in the Growth and Bull paths depends on Carelon care-services mix and MA margin recovery lifting both earnings and the multiple, but those paths carry only 28% combined weight. DCF anchors near 295 on the capex bridge, below spot, which restrains conviction on the long side. The single most damaging risk is a sustained medical-cost-trend spike: with a benefit-expense ratio already near the high-80s, a two-print move above 89.5% would push earnings toward the Cost-Trend path and the target below current levels.

The dashboard below is the whole argument on one page: spot ($419) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The highest-probability bear mechanism is the Base path itself failing, not a tail event. ELV earns a thin 3.6% operating margin on more than 200 billion of premium, so the entire thesis rests on medical-cost trend staying inside priced rate. It has not reliably done so: FY2025 operating cash flow converted at only 0.76x net income, a sign of reserve pressure. Medicaid redeterminations continue to strip lower-cost members while rate updates lag actual utilisation. If the benefit-expense ratio holds above the high-80s for two prints, the margin compresses from 3.6% toward 3.1% and the multiple de-rates in tandem, because the market reprices earnings quality, not just the level. That combination alone moves the fair value from the high-370s toward the Cost-Trend target near 272, roughly 30% below spot, without needing any structural reform.

Key Debate

Gross Margin explains 69% of Monte Carlo outcome variance — the single variable that decides which side is right.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.60 vs analyst floor +0.00 → delta +0.60 (n=43 mgmt / 17 Q&A; 88th pctile across the S&P book, z +1.3).

Flag: ELEVATED — management unusually upbeat vs the analyst floor relative to peers (disconfirmation watch).

News (last 365d, 1000 articles): avg ticker sentiment +0.12 (bullish 20% / bearish 7%)

Scenario Analysis

The tree runs from a structural 'Structural — Medicare/Medicaid Reform / MLR Squeeze' downside ($159) to a 'Bull — Margin Recovery / Re-Rate' bull case ($668); the probability-weighted blend (PWEV $377) is -10% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Medicare/Medicaid Reform / MLR Squeeze (20%, $159). Structural impairment — Medicare/Medicaid reform / MLR squeeze: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 166.26; probability: 0.2.
• Cost-Trend Spike / Rate Inadequacy (17%, $272). Cyclical downturn — membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy weakens for 1–2 years before normalising. Drivers — implied_target: 282.34; probability: 0.17.
• Base — Membership + Premium Growth (35%, $399). Mid-cycle — normalised membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy; disciplined capital allocation; steady returns. Drivers — implied_target: 392.14; probability: 0.35.
• Growth — MA / Care-Services (Optum-style) (20%, $530). Upside — MA + care-services growth lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 529.38; probability: 0.2.
• Bull — Margin Recovery / Re-Rate (8%, $668). Upside tail — sustained tight conditions or a structural re-rate on MA + care-services growth. Drivers — implied_target: 668.59; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $332 and 35% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (69% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 12x terminal FCF multiple → $314. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 19.729999999999997x) implies $533. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.

Across all anchors the spread is 58% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Payers Providers

This name sits in the Health Payers Providers as a managed_care. membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: UNH (managed_care) · CVS (managed_care) · HCA (providers) · ELV (managed_care) · CI (managed_care) · HUM (managed_care) · CNC (managed_care) · DVA (providers) · UHS (providers)

Mapping note: name-level 'Structural — Medicare/Medicaid Reform / MLR Squeeze' (20%) + 'Cost-Trend Spike / Rate Inadequacy' (17%) map to cluster Cost-Trend Spike / Reimbursement-Reform Squeeze (37%); name-level 'Growth — MA / Care-Services (Optum-style)' (20%) + 'Bull — Margin Recovery / Re-Rate' (8%) map to cluster Upside — Margin Recovery / Care-Services (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Cost-Trend Spike / Reimbursement-Reform Squeeze () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The health_payers_providers cycle is the shared macro driver. Driver — medical-cost trend (MLR) + utilization + reimbursement/regulation Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 2% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $27B + PV(terminal) $63B = EV $90B; + net cash → equity $68B ÷ diluted shares 0.22B = $314/share (exit-multiple terminal).

• Gordon (perpetuity-growth) terminal at 2.5% → $437/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 30% vs WACC 8% → above WACC — the build is value-creative.

Peer set

Peer-median fwd P/E → $533; EV/Rev → $509.

Weighted fair-value math

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Managed Care / Health Services multiple (AI re-rating) (base 14x)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 0.1% of revenue; cash conversion (OCF/NI) 76% — earnings not cash-backed.

Catalyst Calendar

• 2026-07-16 (~8d) — Quarterly earnings — est. EPS $6.18 (AV EARNINGS_CALENDAR)
• 2026-10-15 (~99d) — 2027 Medicare Advantage Star Ratings release (authored)
• 2026-11-05 (~120d) — 2027 rate/bid and Medicaid redetermination-completion update (authored)
• 2027-02-10 (~217d) — Carelon services margin and external-growth disclosure (authored)

Forecast Track Record

• EPS surprise: beat 62.5% of the last 8 quarters; average surprise +4.6%.

Competitive Moat

Narrow moat. The moat is Blue Cross Blue Shield licensed scale, regulated membership relationships and a growing Carelon services arm, but managed care is a thin-margin, politically exposed, MLR-capped business; that supports only a modest terminal multiple. Falsifiable: the discount to UNH (~22x) reflects less vertical integration — if Carelon/CarelonRx fail to lift consolidated margin above the low-3s and Medicaid redeterminations keep pressuring MLR, the moat stays narrow and the ~14x multiple is fair rather than cheap.

Moat sources:

• Blue Cross Blue Shield trademark licenses in 14 states (exclusive local franchises)
• Scale membership base and provider-network contracting leverage
• Carelon / CarelonRx vertically-integrated services (Optum-style pivot)
• Regulatory-embedded position in Medicaid/Medicare Advantage

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

What the Market Is Pricing In

At the current price, the market pays 14.3× forward EPS, vs the house DCF terminal 12.0×, and a peer median 19.729999999999997×. The house DCF sits 25% below spot, so the market is pricing in more than the house case — roughly 2.2pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily growth-driven.

Peer Quality & Weighting

Quality-weighted forward P/E: 18.7× (simple median 19.729999999999997×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $268–$427, centre $338 (-19% vs spot); spot sits at the 95th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Margin Recovery / Re-Rate): $668.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (658.0); Revenue CAGR ±3pp (105.0); Terminal × ±15% (87.0); WACC ±1pp (34.0); Capex intensity ±15% (23.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Source Log

Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.

Load-Bearing Assumptions

DCF: WACC 8%, terminal multiple 12×, FY+5 revenue $271B. Triangulation leans 41% on DCF, 29% on PWEV.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Benefit expense ratio (MLR) >= 89.5% (2 consecutive prints → Cost-Trend Spike / Reimbursement-Reform Squeeze). MLR above the high-88s sustained signals medical-cost trend is outrunning priced rate, pushing the margin toward the Cost-Trend / Rate-Inadequacy path rather than Base.
• Full-year adjusted EPS guidance < $30.00 (single event → Cost-Trend Spike / Reimbursement-Reform Squeeze). A guide below the ~$30 Base-path EPS midpoint would confirm the market is repricing earnings power down toward the Cost-Trend scenario, not a transitory miss.
• Medicaid membership < prior-year level (2 consecutive prints → Cost-Trend Spike / Reimbursement-Reform Squeeze). Continued redetermination attrition without offsetting commercial/MA gains removes the volume leg of the Base path and drags revenue growth below the assumed 8%.
• Medicare Advantage Star ratings (share of members in 4+ star plans) < prior-year share (single event → Cost-Trend Spike / Reimbursement-Reform Squeeze). A Star-rating downgrade cuts bonus revenue and removes the MA margin leg, dragging the reported margin from the Base 3.6% toward the Cost-Trend 3.1%.
• Operating cash flow to net income conversion (TTM) < 0.8x (2 consecutive prints → Cost-Trend Spike / Reimbursement-Reform Squeeze). Deteriorating cash conversion flags reserve strengthening or receivables build from cost-trend pressure, corroborating margin stress ahead of the reported MLR.

Fact / Inference / Speculation

• FACT: Spot $419; 52-week range $268–$427; engine rating SELL; base-case target $378 (-10%). (source: Alpha Vantage 2026-06-27, 8 July 2026)
• INFERENCE: Triangulated FV $361 (-14% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.

Recommendation: SELL

Defensive: rating SELL; triangulated fair value $361 (-14% vs spot) — the risk/reward is skewed to the downside on Gross Margin. The debate is Gross Margin — a fundamental call.

Disclosures & Limitations

This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.

• No suitability assessment has been performed for any individual.
• Market data may be delayed or inaccurate; figures are as of the analysis date.
• Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
• Forecasts are uncertain; past performance is not indicative of future returns.
• The author or publisher may hold positions in securities mentioned.
• Users should verify information against primary sources (company filings) before acting.
• Investing involves risk of loss; there is no guarantee any target price is achieved.
• Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.